This bill mandates the Agency for Health Care Administration to conduct or contract for a detailed fiscal impact study to assess the feasibility of implementing provisions related to discounted drug prices under the 340B Drug Pricing Program. The study will explore several requirements, including mandating drug manufacturers to sell drugs to Medicaid pharmacies at no more than the 340B discounted price for drugs on the Medicaid preferred drug list, and requiring pharmacy benefits managers to pay Medicaid pharmacies the discounted price plus a professional dispensing fee. Additionally, it stipulates that drug wholesalers and distributors must sell drugs at the 340B discounted price under similar conditions and prohibits them from altering existing pricing models that would exempt these drugs.

The results of the study are to be submitted to the Governor and the Legislature by January 31, 2027, with the act set to take effect on July 1, 2026. The bill aims to ensure that Medicaid recipients have access to medications at reduced prices while holding manufacturers and distributors accountable for pricing practices.